Emerging Roles of Cannabinoid Receptor CB2 Receptor in the Central Nervous System: Therapeutic Target for CNS Disorders

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2024 Sep 12

PMID 39264450

Authors

Kanchan Bala

Pratyush Porel

Khadga Raj Aran

Affiliations

Soon will be listed here.

Abstract

Rationale: The endocannabinoid system (ECS) belongs to the G protein-coupled receptor family of cell membranes and is associated with neuropsychiatric conditions, and neurodegenerative diseases. Cannabinoid 2 receptors (CB2) are expressed in the central nervous system (CNS) on microglia and subgroups of neurons and are involved in various behavioural processes via immunological and neural regulation.

Objective: The objective of this paper is to summarize and explore the impact of CB2 receptors on neuronal modulation, their involvement in various neurological disorders, and their influence on mood, behavior, and cognitive function.

Results: The activation of CB2 appears to protect the brain and its functions from damage under neuroinflammatory actions, making it an attractive target in a variety of neurological conditions such as Parkinson's disease (PD), multiple sclerosis (MS), Alzheimer's disease (AD), and Huntington's disease (HD). During inflammation, there is an overexpression of CB2 receptors, and CB2 agonists show a strong anti-inflammatory effect. These results have sparked interest in the CB2 receptors as a potential target for neurodegenerative and neuroinflammatory disease treatment.

Conclusion: In conclusion, CB2 receptors signalling shows promise for developing targeted interventions that could positively affect both immune and neuronal functions, ultimately influencing behavioral outcomes in both health and disease.

References

Ashton J, Glass M . The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol. 2008; 5(2):73-80. PMC: 2435344. DOI: 10.2174/157015907780866884. View

Aso E, Andres-Benito P, Ferrer I . Delineating the Efficacy of a Cannabis-Based Medicine at Advanced Stages of Dementia in a Murine Model. J Alzheimers Dis. 2016; 54(3):903-912. DOI: 10.3233/JAD-160533. View

Atwood B, Mackie K . CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol. 2010; 160(3):467-79. PMC: 2931549. DOI: 10.1111/j.1476-5381.2010.00729.x. View

Aychman M, Goldman D, Kaplan J . Cannabidiol's neuroprotective properties and potential treatment of traumatic brain injuries. Front Neurol. 2023; 14:1087011. PMC: 9932048. DOI: 10.3389/fneur.2023.1087011. View

Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D . Role of the cannabinoid system in the transit of beta-amyloid across the blood-brain barrier. Mol Cell Neurosci. 2013; 56:255-62. DOI: 10.1016/j.mcn.2013.06.004. View

Basu S, Dittel B . Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res. 2011; 51(1):26-38. PMC: 4624216. DOI: 10.1007/s12026-011-8210-5. View

Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, Vogel Z . The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 1995; 375(1-2):143-7. DOI: 10.1016/0014-5793(95)01207-u. View

Benito C, Tolon R, Pazos M, Nunez E, Castillo A, Romero J . Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol. 2007; 153(2):277-85. PMC: 2219537. DOI: 10.1038/sj.bjp.0707505. View

Bie B, Wu J, Foss J, Naguib M . An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Curr Opin Anaesthesiol. 2018; 31(4):407-414. PMC: 6035094. DOI: 10.1097/ACO.0000000000000616. View

10.

Block M, Hong J . Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog Neurobiol. 2005; 76(2):77-98. DOI: 10.1016/j.pneurobio.2005.06.004. View

11.

Bouaboula M, Marchand J, Canat X, Bourrie B, Calandra B, Le Fur G . Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur J Biochem. 1996; 237(3):704-11. DOI: 10.1111/j.1432-1033.1996.0704p.x. View

12.

Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S . Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci. 2012; 32(50):18259-68. PMC: 3753072. DOI: 10.1523/JNEUROSCI.4008-12.2012. View

13.

Bow E, Rimoldi J . The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. Perspect Medicin Chem. 2016; 8:17-39. PMC: 4927043. DOI: 10.4137/PMC.S32171. View

14.

Buckley N, McCOY K, Mezey E, Bonner T, Felder C, Glass M . Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000; 396(2-3):141-9. DOI: 10.1016/s0014-2999(00)00211-9. View

15.

Cabral G, Toney D, Fischer-Stenger K, Harrison M, Marciano-Cabral F . Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. Life Sci. 1995; 56(23-24):2065-72. DOI: 10.1016/0024-3205(95)00190-h. View

16.

Calandra B, Portier M, Kerneis A, Delpech M, Carillon C, Le Fur G . Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol. 1999; 374(3):445-55. DOI: 10.1016/s0014-2999(99)00349-0. View

17.

Calderon T, Eugenin E, Lopez L, Sampath Kumar S, Hesselgesser J, Raine C . A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis: regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol. 2006; 177(1-2):27-39. DOI: 10.1016/j.jneuroim.2006.05.003. View

18.

Cargnello M, Roux P . Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011; 75(1):50-83. PMC: 3063353. DOI: 10.1128/MMBR.00031-10. View

19.

Chen M, Wolynes P . Aggregation landscapes of Huntingtin exon 1 protein fragments and the critical repeat length for the onset of Huntington's disease. Proc Natl Acad Sci U S A. 2017; 114(17):4406-4411. PMC: 5410817. DOI: 10.1073/pnas.1702237114. View

20.

Kwan Cheung K, Peiris H, Wallace G, Holland O, Mitchell M . The Interplay between the Endocannabinoid System, Epilepsy and Cannabinoids. Int J Mol Sci. 2019; 20(23). PMC: 6929011. DOI: 10.3390/ijms20236079. View